Akèy › Maladi otoim › Maryland
Etid klinik pou Maladi otoim nan Maryland
21 etid pou Maladi otoim ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT00867269NIAID Centralized Sequencing Protocol
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 100 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT03206099Natural History of Bronchiectasis
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT00943514Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 4 a 69 · Tout sèks · Mizajou Sep 28, 2026 · NCT04339777Environmental Risk Factors for the Anti-synthetase Syndrome
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01276470Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2Volontè an sante akeyi
Laj 4 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT02579967Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT04097561Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Jiska laj 99 · Tout sèks · Mizajou Sep 24, 2026 · NCT00001350Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
1 Month – 100 Years · Tout sèks · Mizajou Sep 24, 2026 · NCT00246857Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- National Naval Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT00977977A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- American Oncology Partners of Maryland, PA, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- National Institutes of Health - Accepting Adult and Juvenile Patients, Bethesda
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- Johns Hopkins Hospital: Division of Rheumatology, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746Daratumumab in Primary Antiphospholipid Syndrome
- Johns Hopkins University, Baltimore
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Sep 16, 2026 · NCT05671757A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104PS-002 for the Treatment of IgA Nephropathy in Adults
- The Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07182227A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 10, 2026 · NCT05027945A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 3 a 99 · Tout sèks · Mizajou Mar 9, 2026 · NCT04304820X-linked Moesin Associated Immunodeficiency
- National Institutes of Health, Bethesda
Ap rekriteEtid obsèvasyon
Laj 4 a 80 · Gason · Mizajou Apr 25, 2025 · NCT06278337Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.